Evaluation of global progress towards HBV and HCV elimination

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts

“…An estimated 57 million people were estimated to be infected with hepatitis C virus (HCV) globally in 2020. 1 If left untreated, HCV leads to cirrhosis in 5%-25% of patients within 10-20 years of infection, with approximately 20% of liver cancer cases and deaths estimated to result from HCV infection globally. [2][3][4] Patients with cirrhosis can experience impaired liver function, portal hypertension, and the development of hepatocellular carcinoma (HCC).…”

“…An estimated 57 million people were estimated to be infected with hepatitis C virus (HCV) globally in 2020 1 . If left untreated, HCV leads to cirrhosis in 5%–25% of patients within 10–20 years of infection, with approximately 20% of liver cancer cases and deaths estimated to result from HCV infection globally 2–4 .…”

Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs

“…By initiating nationwide HCV testing and treatment campaigns, progress has been made toward national HCV elimination goals in Iceland, Egypt and the Republic of Georgia (Table 1), [7][8][9][10] and 13 other countries are estimated to be on track to achieve these goals by 2030. 8 Despite these and other efforts, HCV incidence continues to rise in many regions, leading to continued person-to-person HCV transmission and risk of progressive liver disease for infected individuals. 11,12 With this trend comes an urgency to diagnose and treat patients with HCV, especially among populations with high transmission rates (e.g.…”

“…13 The COVID-19 pandemic diverted resources from healthcare systems, resulting in delayed or halted HCV elimination efforts worldwide. 8 These delays have significant effects on the global disease burden: the first year of the COVID-19 pandemic is estimated to result in an additional 44,800 HCCs and 72,300 excess liver-related deaths worldwide by 2030. 11 In the United States, HCV-related deaths were declining since 2013, but they increased by 4.3% between 2019 and the end of 2020, largely due to the pandemic.…”

Eliminating viral hepatitis B and C in times of war and increasing global refugee crisis

“…This strategy aims to eliminate viral hepatitis as a public health threat by 2030. Unsurprisingly, today most countries in the world are not on track to achieve this goal [3].…”